Published in Cancer Res on April 01, 2008
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov (2011) 1.88
Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene (2010) 1.86
Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci (2011) 1.59
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol (2008) 1.37
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res (2010) 1.32
The pivotal role of integrin β1 in metastasis of head and neck squamous cell carcinoma. Clin Cancer Res (2012) 1.25
Epithelial ovarian cancer experimental models. Oncogene (2013) 1.23
Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A (2013) 1.23
Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol (2012) 1.22
Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis. Mol Cancer (2011) 1.17
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
Laminin-332-integrin interaction: a target for cancer therapy? Curr Med Chem (2008) 1.11
Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res (2009) 1.10
Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (2012) 1.09
Identification of ovarian cancer metastatic miRNAs. PLoS One (2013) 1.09
Steroid receptor coactivator-1 upregulates integrin α₅ expression to promote breast cancer cell adhesion and migration. Cancer Res (2011) 1.08
In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res (2009) 1.08
Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One (2013) 1.07
alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol (2010) 1.01
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol (2009) 1.01
TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer (2014) 1.00
Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) (2011) 0.99
Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget (2014) 0.98
Role of the endothelium during tumor cell metastasis: is the endothelium a barrier or a promoter for cell invasion and metastasis? J Biophys (2009) 0.96
Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression. Oncol Lett (2012) 0.96
Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers (Basel) (2013) 0.95
Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res (2008) 0.95
Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res (2013) 0.95
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One (2012) 0.94
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol (2014) 0.93
Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res (2011) 0.93
Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp Biol Med (Maywood) (2011) 0.93
Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One (2014) 0.92
MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol (2012) 0.92
Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst (2011) 0.92
α5β1 integrin recycling promotes Arp2/3-independent cancer cell invasion via the formin FHOD3. J Cell Biol (2015) 0.92
Mapping the ligand-binding pocket of integrin alpha5beta1 using a gain-of-function approach. Biochem J (2009) 0.91
JNK is a novel regulator of intercellular adhesion. Tissue Barriers (2013) 0.90
Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90
CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget (2014) 0.90
Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One (2011) 0.89
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev (2015) 0.89
E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway. Acta Pharmacol Sin (2012) 0.89
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol (2009) 0.88
Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene (2015) 0.88
Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol (2014) 0.87
Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer. Br J Cancer (2013) 0.87
Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget (2015) 0.85
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. Virchows Arch (2012) 0.85
Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin α5β1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res (2012) 0.84
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis (2013) 0.84
Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci (2012) 0.84
Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV. Br J Cancer (2013) 0.83
Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells. Clin Exp Metastasis (2011) 0.83
Discovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomics. PLoS One (2014) 0.83
Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids. J Ovarian Res (2014) 0.83
Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer (2016) 0.83
MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. Am J Cancer Res (2014) 0.82
Lysophosphatidic Acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. J Oncol (2012) 0.82
Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cell through epithelial-mesenchymal transition. Int J Mol Sci (2014) 0.82
WT1/EGR1-mediated control of STIM1 expression and function in cancer cells. Front Biosci (Landmark Ed) (2011) 0.82
Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin α5β1. J Biol Chem (2014) 0.81
Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells. Curr Med Chem (2013) 0.81
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. Cancer Genomics Proteomics (2016) 0.80
Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene (2016) 0.80
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin. Biochemistry (2011) 0.79
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol (2013) 0.79
Knockdown of liver-intestine cadherin decreases BGC823 cell invasiveness and metastasis in vivo. World J Gastroenterol (2012) 0.79
Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals. Sci Rep (2015) 0.79
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells. Oncotarget (2016) 0.78
Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy? Isr J Chem (2012) 0.78
Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget (2015) 0.78
Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties. Oncotarget (2015) 0.78
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis (2017) 0.78
BMP signaling and its paradoxical effects in tumorigenesis and dissemination. Oncotarget (2016) 0.77
The traditional Tibetan medicine Yukyung Karne exhibits a potent anti-metastatic activity by inhibiting the epithelial to mesenchymal transition and cell migration. BMC Complement Altern Med (2015) 0.77
TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy. Int J Clin Exp Pathol (2015) 0.77
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget (2016) 0.76
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol (2015) 0.76
MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovarian Res (2017) 0.75
The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis. Cancers (Basel) (2015) 0.75
Molecular biology of gynecological cancer. Oncol Lett (2015) 0.75
Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res (2017) 0.75
Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor. Hum Pathol (2016) 0.75
Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma. Cancer Microenviron (2011) 0.75
Inhibition of ovarian cancer proliferation and invasion by pachymic acid. Int J Clin Exp Pathol (2015) 0.75
Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. Oncotarget (2015) 0.75
Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival. Microarrays (Basel) (2013) 0.75
Met and the microenvironment: new insights for ovarian cancer metastasis. Cell Adh Migr (2011) 0.75
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp (2015) 0.75
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun (2016) 0.75
Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J Cancer (2017) 0.75
Exploring the Role of RGD-Recognizing Integrins in Cancer. Cancers (Basel) (2017) 0.75
Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 34.06
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
Cancer of the ovary. N Engl J Med (2004) 11.21
Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer (2004) 6.73
Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev (2001) 5.09
Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol (1994) 4.46
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 3.18
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J (2004) 2.38
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 2.31
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol (2003) 2.14
Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res (1993) 1.90
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Bacterial internalization mediated by beta 1 chain integrins is determined by ligand affinity and receptor density. EMBO J (1993) 1.85
Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene (2005) 1.73
Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol (2001) 1.69
Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol (1999) 1.64
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 1.54
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol (1997) 1.38
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer (2003) 1.35
Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. An in vitro model system for studying tumor cell adhesion and invasion. Exp Cell Res (1985) 1.32
Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res (2005) 1.31
Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res (2000) 1.30
Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer (1994) 1.24
Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer (2004) 1.20
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol (2006) 1.17
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer (2005) 1.13
Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol (2005) 1.12
Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis (2006) 1.11
The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res (2006) 1.07
Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res (2005) 1.06
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem (2002) 1.02
Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res (2004) 1.02
Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res (1997) 0.88
Phorbol ester-induced U-937 differentiation: effects on integrin alpha(5) gene transcription. Am J Physiol Lung Cell Mol Physiol (2000) 0.83
An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest (1994) 0.83
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer (2010) 3.95
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med (2009) 3.55
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J (2002) 2.91
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res (2006) 2.84
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Identification of let-7-regulated oncofetal genes. Cancer Res (2008) 2.56
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 2.50
Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer (2011) 2.49
CD95 promotes tumour growth. Nature (2010) 2.42
Molecular ordering of the initial signaling events of CD95. Mol Cell Biol (2002) 2.36
The CD95 type I/type II model. Semin Immunol (2003) 2.34
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer (2007) 2.31
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol (2010) 2.20
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J (2004) 2.12
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 2.03
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Interdimer processing mechanism of procaspase-8 activation. EMBO J (2003) 2.03
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.89
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta (2013) 1.85
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
The role of receptor internalization in CD95 signaling. EMBO J (2006) 1.80
miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell (2010) 1.76
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov (2012) 1.75
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology (2010) 1.70
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene (2004) 1.66
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61
Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys (2002) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Interpretation of digital mammograms: comparison of speed and accuracy of soft-copy versus printed-film display. Radiology (2002) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol (2008) 1.56
Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A (2009) 1.52
Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein. J Biol Chem (2001) 1.51
High molecular weight polyethylene glycol (PEG 15-20) maintains mucosal microbial barrier function during intestinal graft preservation. J Surg Res (2013) 1.51
Soft-tissue cavernous hemangioma. Radiographics (2004) 1.49
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.46
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol (2011) 1.45
Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell (2005) 1.45
Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity (2006) 1.43
The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A (2002) 1.43
The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res (2006) 1.43
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A (2003) 1.41
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.38
Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol (2005) 1.37
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol (2009) 1.37
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol (2008) 1.37
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33
The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res (2008) 1.33
Apoptosis-independent functions of killer caspases. Curr Opin Cell Biol (2002) 1.32
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.31
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia (2010) 1.31
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol (2012) 1.29
Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J (2006) 1.29